Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Abilify Asimtufii is a long-acting form of aripiprazole, an atypical antipsychotic. It is approved for adults with schizophrenia and as maintenance monotherapy for bipolar I disorder. The medicine comes as an extended-release injectable suspension given into the gluteal muscle by a healthcare professional. Its standard dosing interval is once every two months after appropriate treatment initiation.
read more about abilify asimtufii ...The exact mechanism of aripiprazole in schizophrenia and bipolar I disorder is unknown. Its clinical effects are thought to involve partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. The extended-release injection releases aripiprazole over time, maintaining drug exposure between doses rather than requiring a daily tablet.
Abilify Asimtufii is approved for the treatment of schizophrenia in adults and as maintenance monotherapy for bipolar I disorder in adults. It is not approved for children. Before starting it in someone who has never taken aripiprazole, tolerability to oral aripiprazole must first be established. The medicine is not approved for dementia-related psychosis.
Abilify Asimtufii is injected into the gluteal muscle by a healthcare professional once every two months. The recommended dose is 960 mg, with a 720 mg dose used for selected patients. Current labeling includes a one-day initiation pathway and a 14-day initiation pathway for patients taking oral antipsychotics. People already receiving Abilify Maintena can transition at their next scheduled injection.
Abilify Asimtufii carries a boxed warning about increased mortality in elderly patients with dementia-related psychosis. Other serious risks include neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, compulsive behaviors, low blood pressure, seizures, low white blood cell counts, and cognitive or motor impairment. Weight, blood sugar, movement symptoms, blood pressure, and other adverse effects need clinical monitoring during treatment.
Abilify Asimtufii is given once every two months after treatment has been started correctly. Each dose is administered as an intramuscular gluteal injection.
No. Both contain long-acting aripiprazole, but Abilify Asimtufii is given every two months while Abilify Maintena is normally given once monthly.
No. Abilify Asimtufii must be administered by a healthcare professional as an intramuscular injection into the gluteal muscle.
Yes. Its boxed warning addresses increased mortality in elderly patients with dementia-related psychosis. Abilify Asimtufii is not approved to treat dementia-related psychosis.
ABILIFY ASIMTUFII (aripiprazole) Extended-Release Injectable Suspension Prescribing Information. https://otsuka-us.com/media/static/Abilify-Asimtufii-PI.pdf. Date Accessed September 10, 2026.
ABILIFY ASIMTUFII Medication Guide. https://www.otsuka-us.com/sites/g/files/qhldwo9846/files/media/static/Abilify-Asimtufii-MedGuide.pdf. Date Accessed September 10, 2026.
Aripiprazole Injection. https://medlineplus.gov/druginfo/meds/a615048.html. Date Accessed September 10, 2026.
DailyMed - ABILIFY ASIMTUFII (aripiprazole) Injection, Suspension, Extended Release. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da4c07fd-1130-4341-bb44-63acfa4162be. Date Accessed September 10, 2026.
FDA Label - ABILIFY ASIMTUFII (aripiprazole) Extended-Release Injectable Suspension. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217006s002lbl.pdf. Date Accessed September 10, 2026.